PZ
PZRXQ.US PhaseRx Inc
- Market cap
- USD 1.17K
- P/E
- -
- P/B
- 3.25x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is PZRXQ.US undervalued?
Graham numberThe Graham number of PhaseRx Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PhaseRx Inc fundamental analysis
No fundamental analysis for PhaseRx Inc yet.
PhaseRx Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PhaseRx Inc
PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficien…
Full company profilePhaseRx Inc financial statements
PhaseRx Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2014 | 2015 | 2016 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 1.20M | 375K | 0.00 | - | - | - | - |
| Gross Profit | 1.20M | 375K | 0.00 | - | - | - | - |
| Operating Income | -5.59M | -5.81M | -18.3M | - | - | - | - |
| EBITDA | -4.97M | -5.40M | -17.9M | - | - | - | - |
| Net Income | -6.85M | -7.38M | -20.1M | - | - | - | - |
| EPS | -1.16 | -0.94 | -2.68 | - | - | - | - |
| Balance Sheet | |||||||
| Total Assets | 2.66M | 3.91M | 16.4M | - | - | - | - |
| Total Liabilities | 44.2M | 52.8M | 7.15M | - | - | - | - |
| Shareholders' Equity | -41.5M | -48.9M | 9.30M | - | - | - | - |
| Cash & Short-term Investments | 2.03M | 3.29M | 15.5M | - | - | - | - |
| Total Debt | 12.5M | 19.8M | 5.70M | - | - | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | -4.86M | -5.98M | -9.81M | - | - | - | - |
| Capital Expenditure | 53.0K | 114K | 171K | - | - | - | - |
| Free Cash Flow | -4.91M | -6.09M | -9.98M | - | - | - | - |
| Ratios | |||||||
| ROE | - | - | -216.6% | - | - | - | - |
| ROA | -257.6% | -188.5% | -122.4% | - | - | - | - |
| Net Profit Margin | -570.8% | -1,967.2% | - | - | - | - | - |
| Debt to Equity | - | - | 0.61x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
PhaseRx Inc dividends
PhaseRx Inc has not paid dividends in the last 3 fiscal years.
Who owns PhaseRx Inc
Ownership data of PhaseRx Inc is not available yet.
PhaseRx Inc company profile
- Company name
- PhaseRx Inc
- Ticker
- PZRXQ.US
- Exchange
- USA Stocks
- Listed since
- May 18, 2016
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 10
- Fiscal year end
- December
- Address
- 410 West Harrison Street, Seattle, WA, United States, 98119
- Phone
- 206 805 6300
- Website
- phaserx.com
About PhaseRx Inc
PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 to treat argininosuccinate synthetase deficiency. PhaseRx, Inc., was incorporated in 2006 and is headquartered in Seattle, Washington.
PhaseRx Inc management
4- Dr. Robert W. Overell Ph.D.Co-Founder & Director · born 1956
- Dr. Paul H. Johnson Ph.D.Co-Founder & Director · born 1943
- Prof. Allan S. HoffmanCo-Founder
- Dr. Oliver W. Press M.D., Ph.D.Co-Founder